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Comparison of the Performance of Two Different ALK
Antibody Clones (D5F3 and ALK1) in Anaplastic Large Cell
Lymphoma (ALCL)
Dana Martin MD, Steven Smith MD, PhD, Alden Chesney MD, Terra Lewis,
HT(ASCP) and Raghavendra Pillappa MD

Background

Results

Anaplastic large cell lymphoma (ALCL) is a Tcell lymphoma characterized by CD30
expression and subdivided into anaplastic
lymphoma kinase (ALK) positive and negative
subtypes that show clinically significant
differences in outcomes. The current standard
for evaluating ALK status is
immunohistochemistry using the mouse
monoclonal anti-human CD246 (ALK1) or
fluorescence in situ hybridization. The novel
rabbit monoclonal anti-human CD246 (D5F3) is
proposed as an alternative to ALK1 and FDA
approved for diagnosis of ALK-rearranged lung
adenocarcinoma. However, its performance has
not been systematically tested and compared to
ALK1 in ALCL.

Of the twenty-seven cases, nine were previously
diagnosed as ALK expression positive by ALK-1
staining. Nine cases were positive for ALK
expression by ALK1 staining (34.6%; 1 1+; 0 2+;
8 3+), while fourteen were positive by D5F3
staining (48.1%; 3 1+; 2 2+; 9 3+). There were
no cases that were positive by ALK1, but not by
D5F3, which had identified the five additional
cases. For three of the nine cases (33.3%)
positive by both stains, the D5F3 stained slides
showed greater percentage of cells stained. The
staining intensity was greater by D5F3 in one of
nine cases, the other eight cases showed the
same (3+) intensity by D5F3 and ALK1. FISH
results are available in five cases (19.2%) and
demonstrated 100% concordance with ALK
expression by both IHC stains (four positive, one
negative).

Design
Twenty-seven cases of ALCL were identified
from institutional database searches and
retrieved. A representative slide from each case
was stained using ALK1 and D5F3 in an
automated slide stainer. The intensity of
cytoplasmic staining (graded 0-3, none, faint,
moderate and strong) and percentage of positive
cells (0, <5, 5-50%, 50-75% and >75%) were
evaluated for each individual clone and
subsequently compared between the two clones.

Figure1: Immunohistochemical staining of ALK-1 (A) and D5F3 (B) of a lymph node
fine needle biopsy at 10x magnification with 40x inserts.
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Figure 2. Comparison of stain results.
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Figure 3: Comparison of cytoplasmic stain intensity on a 0-3 scale.
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Figure 4: Comparison of percentage of positive lesional cells.

These findings support the use of D5F3 as an
equivalent and potentially more sensitive
alternative to ALK1 for the evaluation of ALK
positivity in ALCL.

